Drug Manufacturers Withdraw GLP1 Medication From Subsidy Negotiations
Drug manufacturers have withdrawn from the Pharmaceutical Benefits Scheme (PBS) process for GLP1 medication Mounjaro, according to Medicines Australia. The manufacturer cited several reasons for the withdrawal, including the federal government's low price offer for the drug. The PBS advisory committee had previously recommended subsidizing Mounjaro for certain adults with type 2 diabetes. Medicines Australia CEO Liz Dussama stated that the listing process takes too long. Hundreds of thousands of Australians with diabetes may be affected by the decision. The withdrawal follows protracted negotiations with the federal government regarding pricing. Manufacturers specifically noted that the price the Australian government was willing to pay for Mounjaro was too low.
Topics
Developing
- 862d Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore.
- 862d Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
- 862d Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est.
- 862d Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium.
Sources · 7 independent
ABC NewsRadio AU
“the drugs manufacturers withdrawn from the PBS process, citing a range of reasons including that the price Australia was willing to pay for the drug was too low.”
ABC NewsRadio AU
“The PBS advisory committee had recommended GLP1 medication Monjaro be subsidised for some adults with type 2 diabetes. But after protracted negotiations with the federal government, the drugs manufacturers withdrawn from the PBS process”
ABC NewsRadio AU
“Medicines Australia CEO Liz Dussama says the listing process takes too long and is let down by a flawed system”
Unlock the full story
Get a Pro subscription or above to see the live story progression and the full list of independent sources confirming each event as they happen.
Log in to upgrade